|

Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.

RECRUITINGSponsored by University of Freiburg
Actively Recruiting
SponsorUniversity of Freiburg
Started2026-05-30
Est. completion2027-05-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07627568

Summary

The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Diagnosis of acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements
* Hematological relapse after allo-HCT
* 18 years or older

Exclusion Criteria:

* no signed informed consent

Conditions2

Acute Myeloid LeukemiaCancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.